Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. Wegovy (semaglutide) is FDA-approved for weight loss. They contain different molecules with different mechanisms. For weight loss, the proper comparison is Zepbound vs. Wegovy since Zepbound is tirzepatide's FDA-approved weight loss version.
The key difference: indication and molecule
Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist made by Eli Lilly, approved in May 2022 for type 2 diabetes. Its weight loss counterpart is Zepbound, approved in November 2023.
Wegovy contains semaglutide, a GLP-1 receptor agonist made by Novo Nordisk, approved in June 2021 specifically for chronic weight management in adults with BMI 30+ (or 27+ with comorbidities).
This means comparing Mounjaro and Wegovy is comparing across two different axes: different molecules and different indications. The fairer comparisons are Zepbound vs. Wegovy (same indication, different molecules) or Zepbound vs. Mounjaro (same molecule, different indications).
Mounjaro is a diabetes medication that causes impressive weight loss. Wegovy is a weight loss medication. For weight management, the label matters as much as the molecule.
Side-by-side comparison
| Feature | Mounjaro | Wegovy |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Mechanism | Dual GIP/GLP-1 agonist | GLP-1 agonist |
| FDA indication | Type 2 diabetes | Chronic weight management |
| Administration | Weekly injection | Weekly injection |
| Dose range | 2.5–15 mg | 0.25–2.4 mg |
| Weight loss data | ~15–25 lbs (SURPASS, secondary) | ~15% body weight (STEP 1) |
| A1C reduction | ~2.0–2.4% | Not primary endpoint |
| CV benefit | SURPASS-CVOT ongoing | FDA-approved MACE reduction |
| Sleep apnea | Not approved | Not approved (Zepbound is) |
| Insurance for weight loss | Not covered (off-label) | Covered by many plans with PA |
| Weight-loss counterpart | Zepbound | Already approved for weight loss |
For weight loss patients: use the right medication
If you don't have type 2 diabetes and want weight management, here's the practical reality:
- Ask about Zepbound — same molecule, same doses, FDA-approved for weight loss
- Better insurance pathway for weight management
- Additional FDA indication for obstructive sleep apnea
- Single-dose vial option available
- Wegovy is already the correct medication for weight loss
- FDA-approved cardiovascular benefit (MACE reduction)
- Extensive clinical evidence across STEP trial program
- More established prior authorization pathways
Using Mounjaro off-label for weight loss means your insurance likely won't cover it, your prescriber is billing against the wrong diagnosis, and if audited, claims can be denied retroactively. Zepbound eliminates all of these risks — same molecule, proper indication, clean billing. At PEAK, we always prescribe the right label.
What if you're already on Mounjaro?
If your doctor prescribed Mounjaro for type 2 diabetes and you have also lost weight, that is a common and expected effect of tirzepatide. The SURPASS trials consistently showed significant weight reduction as a secondary outcome, even though the primary goal was glycemic control. But if weight management is becoming your primary focus — or if your A1C has normalized and your clinician is reconsidering your treatment plan — the path forward may involve switching to Zepbound. It is the same molecule (tirzepatide) at the same doses, approved specifically for chronic weight management based on the SURMOUNT trial program.
The switch from Mounjaro to Zepbound is clinically straightforward because the active ingredient is identical. You stay on the same dose, the same injection schedule, and the same pen device. The complexity is on the insurance and pharmacy side: your plan may cover one but not the other, or require a new prior authorization. Some plans that covered Mounjaro under a diabetes benefit will not cover Zepbound under a weight management benefit, and vice versa. At PEAK, we handle the transition paperwork and work directly with your insurance to minimize gaps in treatment.
If you are currently on Mounjaro and wondering whether Zepbound makes more sense for your situation, our providers can review your coverage, coordinate the switch, and ensure you don't miss a dose during the transition. Schedule a consultation to discuss your options.
What PEAK prescribes for weight loss
PEAK prescribes Wegovy and Zepbound for weight management. We do not prescribe Mounjaro for weight loss since Zepbound exists for that exact purpose.
Whether semaglutide or tirzepatide is the better fit depends on your health profile, insurance coverage, and treatment goals. Both are excellent medications. Your clinician will help you choose the right one. Schedule a consultation to get started.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
